SNDL: which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns SNDL?
As of Jun 30, 2026, the largest holders reported on Form 13F were Morgan Stanley (3.9% of the shares), Cannell Capital (3.3%) and Tidal Investments (2.0%).
Which institutions hold the most SNDL shares?
Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:
- 1. Morgan Stanley: 3.9%
- 2. Cannell Capital: 3.3%
- 3. Tidal Investments: 2.0%
- 4. Arrowstreet Capital, Limited Partnership: 0.9%
- 5. Citadel Advisors: 0.8%
- 6. Mirae Asset Global Etfs Holdings: 0.8%
- 7. Goldman Sachs Group: 0.7%
- 8. Susquehanna International Group, LLP: 0.7%
- 9. Ewing Morris & Co. Investment Partners: 0.6%
- 10. JPMorgan Chase: 0.5%
How much of SNDL do institutions own?
The 107 institutions that file 13F reported 18.7% of the shares as of Jun 30, 2026.
Sources:All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Dec 31, 2025). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since December 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders of SNDL (all 13F filers)
- Morgan Stanley10.2 MBank or trading desk−1.2 M
- Cannell Capital8.6 MInvestment firm−122 K
- Tidal Investments5.3 MInvestment firm−176 K
- Arrowstreet Capital, Limited Partnership2.4 MQuant or multi-manager−639 K
- Citadel Advisors2.2 MQuant or multi-manager+287 K
- Mirae Asset Global Etfs Holdings2.1 MIndex manager−125 K
- Goldman Sachs Group2.0 MBank or trading desk+788 K
- Susquehanna International Group, LLP1.9 MBank or trading desk+351 K
- Ewing Morris & Co. Investment Partners1.5 MType not verified+180 K
- JPMorgan Chase1.3 MBank or trading desk−136 K
- Shares
- 10.2 M
- Change
- −1.2 M
See more
- Type
- Bank or trading desk
- Value
- $13.8M
- Cannell Capital
- Shares
- 8.6 M
- Change
- −122 K
See more
- Type
- Investment firm
- Value
- $11.7M
- Shares
- 5.3 M
- Change
- −176 K
See more
- Type
- Investment firm
- Value
- $7.2M
- Shares
- 2.4 M
- Change
- −639 K
See more
- Type
- Quant or multi-manager
- Value
- $3.2M
- Shares
- 2.2 M
- Change
- +287 K
See more
- Type
- Quant or multi-manager
- Value
- $2.9M
- Shares
- 2.1 M
- Change
- −125 K
See more
- Type
- Index manager
- Value
- $2.9M
- Shares
- 2.0 M
- Change
- +788 K
See more
- Type
- Bank or trading desk
- Value
- $2.7M
- Shares
- 1.9 M
- Change
- +351 K
See more
- Type
- Bank or trading desk
- Value
- $2.6M
- Ewing Morris & Co. Investment Partners
- Shares
- 1.5 M
- Change
- +180 K
See more
- Type
- Type not verified
- Value
- $2.0M
- Shares
- 1.3 M
- Change
- −136 K
See more
- Type
- Bank or trading desk
- Value
- $1.7M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 18.7% of the shares · top 10: 14.2% · in index firms: 6.8% of the institutional total
Q2 2026: 18.7%
Shares reported by the 107 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Dec 31, 2025). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
This list may be incomplete: we hold 13D and 13G filings made since December 2024. A holder above 5% that has not filed anything since then is not shown here.
No recent filings.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers